Details of the Drug Reposition

General Information of This Drug (ID: DMSDZ8U)

Drug Name
Rintatolimod   DMSDZ8U
Synonyms Ampligen
Therapeutic Class
Antiviral Agents
Drug Type
Protein/peptide drug
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Chronic fatigue syndrome DIS34WJ5 8E49 phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 1/2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00215813) Ampligen in Chronic Fatigue Syndrome. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT04379518) Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients. U.S. National Institutes of Health.